CN Patent

CN108135904A — 用于治疗多发性骨髓瘤的btk抑制剂组合

Assigned to Pharmacyclics LLC · Expires 2018-06-08 · 8y expired

What this patent protects

本文公开了用于治疗恶性血液病的BTK抑制剂(例如依鲁替尼)、免疫调节剂和类固醇的组合的药物组合、给药方案以及施用方法。

USPTO Abstract

本文公开了用于治疗恶性血液病的BTK抑制剂(例如依鲁替尼)、免疫调节剂和类固醇的组合的药物组合、给药方案以及施用方法。

Drugs covered by this patent

revumenib-citrate (REVUMENIB CITRATE)

Patent Metadata

Patent number: CN108135904A
Jurisdiction: CN
Classification: —
Expires: 2018-06-08
Drug substance claim: No
Drug product claim: No
Assignee: Pharmacyclics LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.